Granulomatosis with Polyangiitis (Active) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Granulomatosis with Polyangiitis (Active)
Granulomatosis with Polyangiitis (GPA) is a rare and serious autoimmune disease requiring ongoing treatment. When active, it demands immediate and often expensive medication to manage symptoms and prevent organ damage. TheDrugClub understands the financial burden of such conditions and offers a straightforward way for members to save significantly on their prescription costs, making vital treatments more accessible.
Granulomatosis with Polyangiitis (GPA) is a rare, systemic autoimmune condition characterized by inflammation of small and medium-sized blood vessels, a condition known as vasculitis. This inflammation can lead to the formation of granulomas—small clumps of inflammatory cells—in various organs. When GPA is described as "active," it means the disease is currently causing symptoms and potentially damaging organs, requiring immediate and aggressive treatment.
GPA most commonly affects the respiratory tract (sinuses, lungs) and kidneys, but it can also impact other areas like the eyes, skin, nerves, and joints. Symptoms vary widely depending on the organs involved but can include persistent sinus infections, cough, shortness of breath, kidney dysfunction, skin rashes, joint pain, and nerve damage. Early diagnosis and consistent treatment are crucial to prevent severe, irreversible organ damage and improve long-term outcomes.
Treating active GPA often involves powerful medications designed to suppress the immune system and reduce inflammation. The initial phase, known as induction therapy, typically uses high-dose corticosteroids (like prednisone) in combination with strong immunosuppressants such as cyclophosphamide or rituximab. Once the disease is controlled, patients transition to maintenance therapy, which may involve lower doses of corticosteroids and other immunosuppressants like methotrexate, azathioprine, or mycophenolate mofetil. These medications are often life-long
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.